In 2000 Pfizer began a partnership with the South African Ministry of Health to donate the antifungal Diflucan® through government hospitals to patients lacking even the most basic health care. Based on the initial success in reaching patients, the South African partnership was expanded and became the Diflucan® Partnership Program.
Over 66 million tablets have been shipped to clinics and governments since the program’s outset. Governmental and nongovernmental organizations in developing countries with HIV/AIDS prevalence of greater than 1 percent are given priority. The following countries are eligible for the program:
| Afghanistan | Malawi |
| Angola | Maldives |
| Argentina | Mali |
| Bangladesh | Mauritania |
| Barbados | Mozambique |
| Belize | Myanmar |
| Benin | Namibia |
| Bhutan | Nepal |
| Botswana | Niger |
| Burkina Faso | Nigeria |
| Burundi | Panama |
| Cambodia | Papua New Guinea |
| Cameroon | Paraguay |
| Cape Verde | Peru |
| Central African Republic | Rwanda |
| Chad | Samoa |
| Colombia | São Tomé and Príncipe |
| Comoros | Senegal |
| Congo | Seychelles |
| Costa Rica | Sierra Leone |
| Côte d’Ivoire | Solomon Islands |
| Democratic Republic of Congo | Somalia |
| Djibouti | South Africa |
| Dominican Republic | Sudan |
| El Salvador | Suriname |
| Equatorial Guinea | Swaziland |
| Eritrea | Tanzania |
| Ethiopia | Thailand |
| Gabon | Togo |
| Gambia | Trinidad and Tobago |
| Ghana | Tuvalu |
| Guatemala | Uganda |
| Guinea | Ukraine |
| Guinea-Bissau | Vanuatu |
| Guyana | Venezuela |
| Haiti | Yemen |
| Honduras | Zambia |
| Jamaica | Zimbabwe |
| Kenya | |
| Laos | |
| Lesotho | |
| Liberia | |
| Madagascar |
